Boston Scientific Announces Schedule for EuroPCR 2009

PRNewswire NATICK, Mass. (NYSE:BSX)

NATICK, Mass., May 15 <u>/PRNewswire-FirstCall/</u> -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's events and news announcements at the annual EuroPCR Scientific Program, which runs from May 19 to 22 in Barcelona, Spain.

"We are pleased to be announcing additional analyses from the landmark SYNTAX trial, including an evaluation of European economic outcomes, as well as insights on the design and practical applications of the SYNTAX Score™," said Keith D. Dawkins, M.D., Senior Vice President and Associate Chief Medical Officer at Boston Scientific. "The SYNTAX Score is breaking new ground by scientifically defining a measure for anatomical complexity that is intended to provide physicians with an important tool for assessing treatment options for high-risk patients with left main and three-vessel disease."

Schedule of Events (all times are local Barcelona and all presentations take place in the International Convention Center)

Tuesday, May 19

• SYNTAX-LE MANS Study. A. Pieter Kappetein, M.D., Ph.D., will present 15-month outcomes from an angiographic substudy of patients with left main disease from the SYNTAX trial, during a late-breaking clinical trial session at 5:00 p.m. in the main arena. The SYNTAX trial compares percutaneous coronary intervention (PCI) using the TAXUS® Express2® Paclitaxel-Eluting Coronary Stent System to coronary artery bypass surgery (CABG) in patients with left main disease and/or three-vessel disease. The substudy analysis includes 149 patients treated with PCI and 114 patients treated with CABG. The Company plans to issue a press release at this time.

• SYNTAX Score™ website. A new website will be launched dedicated to the understanding and use of the SYNTAX Score, a novel angiographic tool used to measure the complexity of coronary artery disease. The Company plans to issue a press release at this time.

Wednesday, May 20

• SYNTAX Score: Practical Applications. Dr. Kappetein will present an overview of the design and application of the SYNTAX Score, during a podium session at 9:15 a.m. in Room 1.

• SYNTAX Trial: Evaluation of Economic Outcomes. Ben van Hout, M.D., will present an analysis of one-year result from the SYNTAX trial focusing on resource utilization among different European countries, during an abstract session 12:20 p.m. in Room 129. The Company plans to issue a press release at this time.	
• Case Review Session - Diabetic Patients. Boston Scientific will sponsor a case review session titled "Challenging t experts: percutaneous coronary intervention decision making for diabetic patients," chaired by Dariusz Dudek, M.D., 12:00 - 1:30 p.m. in Room 120/121. The session will provide expert opinions on real-life examples of challenging dial patients with coronary artery disease.	from
• Case Review Session - Infra-Inguinal Interventions. Boston Scientific will sponsor a case review session titled "Challenges in infra-inguinal interventions: what technology for what lesions?," chaired by Horst Sievert, M.D., from 56:30 p.m. in Room 122/123. The session will explore the use of less-invasive technology in the treatment of infra-ingular lesions and describe some of the technical challenges of endovascular treatment of these lesions.	
Thursday, May 21	
• TAXUS Woman Study: Gender Differences in Outcomes. Robert T. Gerber, M.D., will present an analysis compared long-term clinical outcomes in 2,271 patients who received a TAXUS paclitaxel-eluting stent in the TAXUS I, II, IV, V ATLAS studies, during an abstract session at 9:41 a.m. in Room 128.	
Case Review Session - Left Main Stenosis. Boston Scientific will sponsor a case review session titled "Treating left main stenosis: practical application of new data from the SYNTAX-LE MANS trial," chaired by Marie-Claude Morice, and A.P. Kappetein, M.D., from 12:00 - 1:30 p.m. in Room 1. The session will explore revascularization options for le main disease in light of new data from the SYNTAX-LE MANS study.	M.D.

 SYNTAX Trial: Early and Late Graft Occlusion and Stent Thrombosis. Ted. E. Feldman, M.D., will present an a of one-year rates of graft occlusions and stent thrombosis from patients enrolled in the SYNTAX trial, during an abs session at 12:19 p.m. in Room 129. 	
• PROMUS® Stent. Eberhard Grube, M.D., will present one-year results from the SPIRIT V Registry, during an abstr session at 3:06 p.m. in Room 118/119. SPIRIT V is a post-approval registry of the XIENCE V® (PROMUS®) Stent.	
• ARRIVE 1 and 2 Registries: Insights in Saphenous Vein Graft Lesions. Emmanouil S. Brilakis, M.D., will preser comparison of two-year clinical outcomes of patients with saphenous vein graft (SVG) lesions versus native corona artery lesions, during an abstract session at 3:19 p.m. in Room 118/119.	
• TAXUS OLYMPIA Registry. Waqar Ahmed, M.D., will present an analysis of geographic differences among 22,000 patients in the TAXUS OLYMPIA registry, during an abstract session at 5:28 p.m. in Room 118/119. The analysis of compare baseline and procedural characteristics, and one-year outcomes across four geographic regions (Asia, Eulatin America, and Middle East/North Africa).	will
• Utility of SYNTAX Score. Davide Capodanno, M.D., will present an analysis of the SYNTAX Score titled "Usefulne the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left mair coronary artery disease," during an abstract session at 5:35 p.m. in Room 127.	
Company Booth. Boston Scientific will present its latest cardiovascular products at booth #D06 in the Exhibit Hall, included rug-eluting stent platforms and IVUS technologies. The booth will also include product and program displays offering phand patient resources.	
Corporate Responsibility. Boston Scientific is committed to making more possible this year at EuroPCR by sponsoring charity events. On Tuesday May 12th, ten Boston Scientific staff members set off on a 1,440 km, eight-day tandem cycle from the Company's London office to Barcelona. Their goal is to help raise funds for Heart Research UK, a charity that spioneering research into the treatment, diagnosis and prevention of heart disease. Additionally, Boston Scientific will spocharity run to raise funds for the Spanish Heart Foundation. The 4 km run will begin at 7:00 a.m. on Wednesday May 20th participants can register onsite at the Boston Scientific exhibit booth.	e trip upports onsor a

TAXUS, Express, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott.

The safety and effectiveness of the TAXUS Express Stent have not been established in patients with left main or three-vessel disease.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation

> Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: http://www.bostonscientific.com/